
Global R&D Pipeline
My Favorite
Hot Targets:
IL4R
Back
Total number of drugs
96
Phase II and later clinical stages
13.5%
Involving companies
112
Main therapeutic areas
Immune System Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PM-1268 | PM-1268 | Bispecific antibody | Neoplasms | IL-31 inhibitors IL-4Rα inhibitors | Biotheus, Inc. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | PM-1268 | - | - | detail > | |
| CN117924499 | CN117924499 | Monoclonal antibody | Immune System Diseases Infectious Diseases Eye Diseases Hemic and Lymphatic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases | - | KANGLITAI BIOMEDICAL (QINGDAO) CO., LTD | KANGLITAI BIOMEDICAL (QINGDAO) CO., LTD | Discovery | - | - | - | - | - | - | - | - | - | CN117924499 | - | - | detail > | |
| WO2024242455 | WO2024242455 | Nanobody | Other Diseases | - | Industry Academic Cooperation Foundation of Hongik UniversityYonsei Industry-Academic Cooperation Foundation | Industry Academic Cooperation Foundation of Hongik UniversityYonsei Industry-Academic Cooperation Foundation | Discovery | - | - | - | - | - | - | - | - | - | WO2024242455 | - | - | detail > | |
| CN116887858 | CN116887858 | Monoclonal antibody | Immune System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases | - | Regeneron Pharmaceuticals, Inc.Sanofi Biotechnology SAS | Sanofi Biotechnology SASRegeneron Pharmaceuticals, Inc. | Discovery | - | - | - | - | - | - | - | - | - | CN116887858 | - | - | detail > | |
| IL-4Ra (Generian) | IL-4Ra (Generian) | Small molecule drug | - | IL-4Rα modulators | Generian Pharmaceuticals, Inc. | Generian Pharmaceuticals, Inc. | Discovery | - | - | - | - | - | - | - | - | - | IL-4Ra (Generian) | - | - | detail > | |
| BET207-01 | BET207-01 | Nanobody | Immune System Diseases Infectious Diseases Congenital Disorders Otorhinolaryngologic Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | IL-4Rα inhibitors | Bonentai (Shandong) Biomedical Technology Group Co., Ltd. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | BET207-01 | - | - | detail > | |
| PM-1017 | PM-1017 | Bispecific antibody | Neoplasms | IL-4Rα inhibitors IL-5 inhibitors | Biotheus, Inc. | - | Discontinued (in Preclinical) | Discontinued (in Preclinical) | - | - | - | - | - | - | - | - | PM-1017 | - | - | detail > | |
| IL-4R(Amgen, Inc.) | IL-4R(Amgen, Inc.) | Recombinant protein | Immune System Diseases Respiratory Diseases | IL-4Rα modulators | Amgen, Inc. | - | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | - | IL-4R(Amgen, Inc.) | - | - | detail > | |
| Bizaxofusp | Bizaxofusp | Antibody toxin conjugate | Neoplasms Nervous System Diseases Other Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | IL-4Rα modulators | Neurocrine Biosciences, Inc. | - | Discontinued (in Phase 2) | - | - | - | - | Fast Track(United States) Orphan Drug(European Union) Orphan Drug(United States) | - | - | - | - | Bizaxofusp | - | - | detail > | |
| IL4R/IL25-BsAb (Novarock) | IL4R/IL25-BsAb (Novarock) | Bispecific antibody | Immune System Diseases Congenital Disorders Respiratory Diseases Skin and Musculoskeletal Diseases | IL-25 inhibitors IL-4Rα inhibitors | Novarock Biotherapeutics Ltd. | Novarock Biotherapeutics Ltd. | Discovery | - | - | - | - | - | - | - | - | - | IL4R/IL25-BsAb (Novarock) | - | - | detail > |
Total 96 data
1
2
3
4
5
6
...
9
10


